[
  {
    "ts": "2025-12-15T13:30:00+00:00",
    "headline": "Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial",
    "summary": "FOSTER CITY, Calif., December 15, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically no",
    "url": "https://finance.yahoo.com/news/gilead-investigational-single-tablet-regimen-133000257.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "c6fa1bc9-b3e4-3c94-b9f6-22e7aab07229",
      "content": {
        "id": "c6fa1bc9-b3e4-3c94-b9f6-22e7aab07229",
        "contentType": "STORY",
        "title": "Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial",
        "description": "",
        "summary": "FOSTER CITY, Calif., December 15, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically no",
        "pubDate": "2025-12-15T13:30:00Z",
        "displayTime": "2025-12-15T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/2433b898ef0387696c60aafa16b30c90",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bKjNGKGkeKH_jRwSGvNmXQ--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2433b898ef0387696c60aafa16b30c90.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MnJtQU8SyEt.46kXZMiNaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2433b898ef0387696c60aafa16b30c90.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-investigational-single-tablet-regimen-133000257.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-investigational-single-tablet-regimen-133000257.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-15T14:59:00+00:00",
    "headline": "RCUS Stock Down on Decision to Discontinue GILD Partnered Study",
    "summary": "Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.",
    "url": "https://finance.yahoo.com/news/rcus-stock-down-decision-discontinue-145900718.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1612f023-d24a-3d96-a345-5132ac32a501",
      "content": {
        "id": "1612f023-d24a-3d96-a345-5132ac32a501",
        "contentType": "STORY",
        "title": "RCUS Stock Down on Decision to Discontinue GILD Partnered Study",
        "description": "",
        "summary": "Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.",
        "pubDate": "2025-12-15T14:59:00Z",
        "displayTime": "2025-12-15T14:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H9Y3er.afSc3GhCdnEPJDg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A8kFZZ9VHNy5RXuATQIZdw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rcus-stock-down-decision-discontinue-145900718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rcus-stock-down-decision-discontinue-145900718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RCUS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-15T21:18:00+00:00",
    "headline": "Alger Russell Innovation Index Updates for Fourth Quarter 2025",
    "summary": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.",
    "url": "https://finance.yahoo.com/news/alger-russell-innovation-index-updates-211800012.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "0830191c-4330-3350-9f60-53c4e1d46ff2",
      "content": {
        "id": "0830191c-4330-3350-9f60-53c4e1d46ff2",
        "contentType": "STORY",
        "title": "Alger Russell Innovation Index Updates for Fourth Quarter 2025",
        "description": "",
        "summary": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.",
        "pubDate": "2025-12-15T21:18:00Z",
        "displayTime": "2025-12-15T21:18:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/3c51d59f16e42531ecde106768c7fee7",
          "originalWidth": 400,
          "originalHeight": 77,
          "caption": "Alger's Logo (PRNewsfoto/Alger)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isY6Q5lqlZ5tIc5TfFsYHQ--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/3c51d59f16e42531ecde106768c7fee7.cf.webp",
              "width": 400,
              "height": 77,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/reYcEsMQ5MI65ZoZHC9P5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/3c51d59f16e42531ecde106768c7fee7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/alger-russell-innovation-index-updates-211800012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/alger-russell-innovation-index-updates-211800012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CCC"
            },
            {
              "symbol": "FFIV"
            },
            {
              "symbol": "GNTX"
            },
            {
              "symbol": "CORT"
            },
            {
              "symbol": "EA"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "QRVO"
            },
            {
              "symbol": "UTHR"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]